GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (STU:UNC) » Definitions » Shiller PE Ratio

UCB (STU:UNC) Shiller PE Ratio : 20.17 (As of May. 01, 2024)


View and export this data going back to . Start your Free Trial

What is UCB Shiller PE Ratio?

As of today (2024-05-01), UCB's current share price is €124.25. UCB's E10 for the fiscal year that ended in Dec23 was €6.16. UCB's Shiller PE Ratio for today is 20.17.

The historical rank and industry rank for UCB's Shiller PE Ratio or its related term are showing as below:

STU:UNC' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.79   Med: 16.94   Max: 26.17
Current: 20.03

During the past 13 years, UCB's highest Shiller PE Ratio was 26.17. The lowest was 8.79. And the median was 16.94.

STU:UNC's Shiller PE Ratio is ranked better than
69.33% of 150 companies
in the Biotechnology industry
Industry Median: 34.975 vs STU:UNC: 20.03

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

UCB's adjusted earnings per share data of for the fiscal year that ended in Dec23 was €1.760. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is €6.16 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


UCB Shiller PE Ratio Historical Data

The historical data trend for UCB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Shiller PE Ratio Chart

UCB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.35 16.22 17.49 11.89 12.69

UCB Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.49 - 11.89 - 12.69

Competitive Comparison of UCB's Shiller PE Ratio

For the Biotechnology subindustry, UCB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UCB's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UCB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where UCB's Shiller PE Ratio falls into.



UCB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

UCB's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=124.25/6.16
=20.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB's E10 for the fiscal year that ended in Dec23 is calculated as:

For example, UCB's adjusted earnings per share data for the fiscal year that ended in Dec23 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec23 (Change)*Current CPI (Dec23)
=1.76/128.2922*128.2922
=1.760

Current CPI (Dec23) = 128.2922.

UCB Annual Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 2.200 99.086 2.848
201512 6.500 100.572 8.292
201612 5.520 102.614 6.901
201712 8.000 104.804 9.793
201812 8.480 107.252 10.144
201912 8.200 108.065 9.735
202012 3.770 108.511 4.457
202112 5.450 114.705 6.096
202212 2.140 126.578 2.169
202312 1.760 128.292 1.760

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


UCB  (STU:UNC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


UCB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of UCB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


UCB (STU:UNC) Business Description

Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (STU:UNC) Headlines

No Headlines